T-cell-mediated immunity has the ability to produce durable antimelanoma responses, resulting in improved survival of patients with advanced melanoma. Antigen presentation is a key determinant of T-cell responses. Gamma-interferoninducible lysosomal thiol reductase (GILT) is critical for MHC class II-restricted presentation of multiple melanoma antigens to CD4 + T cells. However, GILT expression in melanoma has not been defined. We evaluated GILT and MHC class II expression in human primary and metastatic melanomas and nevi using immunohistochemical analysis. GILT staining in melanocytes was observed in 70% of primary and 58% of metastatic melanomas versus 0% of nevi. When present, the GILT staining intensity in melanocytes was typically faint. Both GILT and MHC class II expression were increased in melanocytes of primary and metastatic melanomas compared with nevi. GILT staining in antigen-presenting cells (APCs) was detected in 100% of primary and metastatic melanomas versus 31% of nevi, and it was typically intense. GILT expression was increased in APCs of primary and metastatic melanomas compared with nevi, whereas MHC class II had equivalent high expression in APCs of all melanocytic lesions. GILT staining in keratinocytes was detected in 67% of primary melanomas versus 14% of nevi and 6% of metastatic melanomas. GILT, but not MHC class II, expression was increased in keratinocytes of primary melanomas compared with nevi and metastases. GILT expression is anticipated to result in improved presentation of melanoma antigens and more effective antimelanoma T-cell responses. GILT expression may be a biomarker of immune recognition of melanoma. Melanoma Res 26:125-137
Introduction
Gamma-interferon-inducible lysosomal thiol reductase (GILT or IFI30 protein) is an enzyme localized to endosomes, lysosomes, and phagosomes that is required for efficient MHC class II-restricted presentation of melanoma antigens (reviewed in [1, 2] ). GILT serves a unique function of reducing protein disulfide bonds in the endocytic compartment, as it is the only reductase known to reside in this compartment. Previously, GILT has been shown to be constitutively expressed in professional antigen-presenting cells (APCs), including B cells, monocytes/macrophages, and bone marrow-derived dendritic cells [3] [4] [5] . GILT expression can be induced in other cell types such as melanoma cell lines by interferon (IFN)-γ [6] . We have demonstrated that the reductase function of GILT enhances the MHC class II-restricted presentation of a subset of epitopes from disulfide bond-containing proteins, presumably through exposing buried epitopes for MHC class II binding [7] . We and others have shown that GILT is required for optimal presentation of the melanoma antigens tyrosinase and tyrosinase-related protein 1 [6, 8] . Given that other melanoma antigens, such as gp100, TRP2, and NY-ESO-1, contain disulfide bonds, GILT is likely to enhance the presentation of these antigens as well [9] [10] [11] .
GILT expression in the tumor microenvironment likely has a substantial impact on the presentation of melanoma antigens. Although antigen presentation by migratory dendritic cells in secondary lymphoid organs is a major mechanism for activating naive T cells and priming the T-cell antitumor response, antigen presentation in tissue sites is an important component of memory and effector T-cell function and can also support the activation and differentiation of naive T cells [12, 13] . Melanoma cells, APCs, and keratinocytes may contribute to MHC class IIrestricted presentation in melanoma tumors. Melanoma cells may express MHC class II molecules and are capable of presenting endogenous membrane-bound and cytoplasmic antigens on MHC class II [14, 15] . Melanoma tumor cells directly presenting antigens are capable of activating naive T cells [12] . An earlier study demonstrated that MHC class II-expressing human metastatic melanoma cell lines have absent or low GILT expression, resulting in diminished MHC class II-restricted presentation of naturally occurring epitopes [6] . This study suggests that the lack of GILT expression in MHC class II-expressing melanomas may be a mechanism of tumor immune evasion. It is unknown whether diminished GILT expression is found in melanoma in vivo. Our study evaluated whether there is loss of GILT in melanoma cells in advanced melanoma lesions. As APCs within the tumor are also capable of activating naive T cells and modulating the function of tumor-infiltrating lymphocytes [12] , we evaluated GILT expression in tumor-infiltrating APCs. In addition, induced expression of MHC class II on keratinocytes has been described in inflammatory skin diseases, as well as a small number of tumor cases including melanoma [16] [17] [18] [19] . As cultured human keratinocytes are capable of MHC class II-restricted processing and presentation, and animal models of autoimmunity suggest that antigen presentation by keratinocytes may initiate naive T-cell responses [20] [21] [22] , we investigated whether keratinocytes express GILT in melanoma.
As GILT expression in melanoma tumors has not been established, we determined whether the cell types capable of antigen presentation in melanoma express GILT for optimal MHC class II-restricted presentation of melanoma antigens. We evaluated GILT expression relative to MHC class II expression in melanocytes, APCs, and keratinocytes of human primary and metastatic melanomas in comparison with benign nevi by immunohistochemical analysis. We found a significantly increased GILT protein expression in melanocytes, APCs, and keratinocytes in melanoma lesions compared with nevi. The implications of these findings in antigen presentation in the tumor microenvironment and in T-cell-mediated recognition of melanoma have been discussed.
Methods

Sample size determination and tissues
Using the PubMed database, we identified 12 studies that examined the expression of any MHC class II allele in melanocytes in human melanocytic lesions [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Using the pooled probabilities from prior studies, the negative binomial distribution was used to determine the sample size required to be at least 80% certain that we would identify MHC class II staining in 10 primary and 10 metastatic melanomas. We selected deeper primary melanomas with a Breslow depth of at least 1.5 mm, reported to have a higher frequency of MHC class II expression [23, 28, 30, 32] , to reduce the sample size of primary melanoma lesions required. Deidentified formalin-fixed, paraffin-embedded biopsy specimens of 28 primary melanomas, 20 metastatic melanomas, and 29 benign nevi as controls were obtained from the Yale University Department of Dermatology and Arizona Dermatopathology. One primary and one metastatic melanoma had insufficient tissue, giving a final sample size of 27 primary and 19 metastatic melanomas. As nevi occur in younger patients compared with melanoma, patients below 30 years of age were excluded. Patient and lesion characteristics are listed in Table 1 . The study was reviewed by the Office of Research Administration at the University of Arizona College of Medicine Phoenix and determined to be exempt from review by the Institutional Review Board.
Immunohistochemistry
Previously optimized staining protocols for GILT and MHC class II [5] were modified to use a red chromagen to avoid confusion of melanin pigment with a brown chromagen. Formalin-fixed, paraffin-embedded tissues were sectioned at 3-5 μm and mounted on charged glass slides. Immunohistochemical staining was performed using automated protocols on a Benchmark Ultra immunostainer (Ventana Medical Systems, Tucson, Arizona, USA). Heat-induced epitope retrieval was performed using Cell Conditioning-1 solution (Ventana Medical Systems). Sections were stained with rabbit anti-GILT polyclonal antibody (Catalog# S1265, 1 : 3000 dilution; Epitomics, Burlingame, California, USA) and mouse monoclonal antibody recognizing MHC class II alleles, HLA-DR/DP/DQ (clone CR3/43, 1 μg/ml; Abcam, Cambridge, Massachusetts, USA), followed by detection using the ultraView Universal Alkaline Phosphatase Red Detection Kit (Ventana Medical Systems), hematoxylin II counterstain, and Bluing reagent (Ventana Medical Systems). Universal negative control serum (BioCare, Concord, California, USA) served as an antibody negative control; in each specimen, no staining was detected with the universal negative control serum. Tonsil tissue served as a positive control.
Melanocytes (including nevus melanocytes and melanoma cells), tumor-infiltrating APCs, and keratinocytes were identified on the basis of morphological and histological characteristics. Nevus melanocytes were identified by the presence of a larger nucleus than keratinocytes, the lack of desmosomes, and their characteristic arrangement in nests. Malignant melanocytes were identified by nuclear changes associated with malignancy including variation in nuclear size, irregular chromatin pattern, increased nucleolar size, and increased mitotic figures. In addition, malignant melanocytes lose the symmetry and maturation of nests found in nevi. APCs can only be identified when they are positively stained and exhibit a dendritic or branched shape. Keratinocytes are the predominant cell type in the skin epithelium and are identified by their characteristic shape, differentiation within the stratified epithelial layer, and the presence of desmosomes connecting adjacent keratinocytes. Staining on each section was scored with light microscopy simultaneously by a board-certified dermatopathologist (R.B.) and a dermatologist (K.T.H.), with agreement reached in each case. Diagnostic histologic features are evident on evaluation of sections stained by immunohistochemical staining and preclude a blinded study. Photomicrographs were acquired using a BX45 microscope, a DP71 digital camera, and cellSens Entry 1.6 software (Olympus, Waltham, Massachusetts, USA). USA), and exposed to film. Subsequently, the blot was washed and reprobed with mouse anti-GAPDH mAb (clone GA1R, 0.33 µg/ml; Thermo Scientific, Waltham, Massachusetts, USA) as a loading control, followed by HRPconjugated goat anti-mouse IgG (1 : 5000; Jackson ImmunoResearch Laboratories).
Statistical analysis
Fisher's exact test was used to compare GILT and MHC class II staining (positive versus negative) across the three types of lesions (nevi, primary melanomas, and metastatic melanomas). The Kruskal-Wallis test was used to compare the frequency and intensity of GILT and MHC class II staining among the three lesion types. If the global test showed that there was a statistically significant difference across the three lesion types, three pairwise comparisons were performed using the same test. Multiple comparisons were adjusted for using the Bonferroni method, considering a P-value less than 0.05 divided by 3 (number of comparisons made)that is, less than 0.0167as significant. To investigate whether age confounded the results, the analysis described above was carried out within strata defined by age (< 60 or ≥ 60 years). Next, we determined whether GILT staining was correlated with MHC class II staining. The association between GILT and MHC class II staining (positive versus negative) was examined using Fisher's exact test within each lesion type. Spearman's rank correlation coefficient (Spearman's ρ) was estimated for the frequency and intensity of these two proteins within each lesion type, and whether the coefficient was equal to 0 or not was tested. Unless otherwise specified, a P-value less than 0.05 was considered significant. Analyses were carried out using Stata, Data Analysis, and Statistical Software (Version 13, 2013; Stata Corp., College Station, Texas, USA).
Results
Characterization of GILT and MHC class II staining in melanocytic lesions
The sensitivity and specificity of staining were tested using multiple approaches. Immunohistochemical staining was detected in B cell lines known to express GILT and MHC class II (data not shown). The same staining pattern was observed using multiple GILT and MHC class II antibodies and in paired frozen and paraffinembedded melanoma specimens (data not shown). To further evaluate the specificity of the GILT antibody, three melanoma tumor lysates were analyzed by immunoblotting. A single band at ∼ 30 kDa, corresponding to mature GILT protein, was detected in melanoma 2, in melanoma 3 (faint band), and in the GILT-expressing Raji B cell line (positive control; Fig. 1a , lanes 2, 3, and 4, respectively). GILT was not detected in melanoma 1 nor in the epithelial cell line, HEK-293T (negative control; Fig. 1a , lanes 1 and 5). No nonspecific bands were observed. GAPDH was used as a loading control on immunoblotting and revealed similar levels in each lysate.
We evaluated GILT and MHC class II staining in human melanocytic lesions using immunohistochemical analysis. Cases were first scored as positive or negative for GILT and MHC class II expression in each cell type. The frequency of staining was scored as 0 (no staining), less than 5% of cells, 5-20% of cells, or greater than 20% of cells of the total respective cell type for melanocytes and keratinocytes and of the total cell mass for APCs. As illustrated in Fig. 1b for melanocytes, the staining intensity was scored as absent (no staining), faint (blush with no vesicular staining), intermediate (vesicular pattern for GILT similar to B cells [5] ), or intense (similar to GILT staining in dendritic cells in lymphoid tissues [5] ). Consistent with variable GILT expression in melanoma tumors observed on immunoblotting ( Fig. 1a ) and with prior reports of variable MHC class II expression in melanoma tumors [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] , melanoma cells exhibited a range of GILT and MHC class II expression levels ( Fig. 1b ).
GILT and MHC class II expression in melanocytes is increased in primary and metastatic melanomas compared with nevi First, we evaluated melanocytes of nevi, primary melanomas, and metastatic melanomas for GILT and MHC class II expression by immunohistochemical analysis.
Staining for GILT was detected in melanocytes of 19/27 (70%) primary melanomas and 11/19 (58%) metastatic melanomas, compared with 0/29 nevi ( Fig. 2a ). The percentage of primary and metastatic melanoma cases with GILT expression in melanocytes was significantly increased compared with nevi ( Fig. 2a ). We further evaluated GILT staining in melanocytes using frequency and intensity as semi-quantitative assessments of expression. Primary and metastatic melanomas exhibited a range of frequencies of GILT-expressing melanocytes, and the predominant GILT staining intensity was faint ( Fig. 2b-d) . The frequency and intensity of GILT expression in melanocytes were increased in primary and metastatic melanomas compared with nevi ( Fig. 2b and c ). There were no differences in the percentage, frequency, nor intensity of GILT expression in melanocytes between primary and metastatic lesions. These data show that GILT expression is increased in malignant melanocytes compared with benign melanocytes.
For comparison, we evaluated MHC class II expression in melanocytes. MHC class II-staining melanocytes were present in 0/29 nevi, 14/27 (52%) primary melanomas, and 6/19 (32%) metastatic melanomas ( Fig. 2e ). The percentage of primary and metastatic melanoma cases with MHC class II expression in melanocytes was increased compared with nevi. Likewise, the frequency and intensity of MHC class II expression in melanocytes were increased in primary and metastatic melanomas compared with nevi ( Fig. 2f-h ). There were no differences in the overall percentage, frequency, nor intensity of MHC class II expression in melanocytes between primary and metastatic melanomas. Together, these data show that, on the basis of overall positivity, frequency, and intensity, both GILT and MHC class II expression are increased in melanocytes of primary and metastatic melanomas compared with nevi.
Compared with nevi, melanomas occur in older individuals. To address the possibility of whether the difference in patient age between the melanomas and nevi confounded the results, we stratified the cases into two categories (patients < 60 years and patients ≥ 60 years) and carried out the same analyses as above. The same qualitative changes were observed graphically in the two age categories as in the overall group (data not shown). There was a similar significant relationship, demonstrating increased GILT staining, frequency, and intensity in melanomas, identified within each of the two age categories as the overall comparison ( Table 2 ). These data suggest that the observed differences in GILT expression are due to lesion type, rather than age. To investigate whether GILT and MHC class II expression in vivo supports prior work with metastatic melanoma cell lines, suggesting absent or low GILT expression in MHC class II-expressing melanomas as a mechanism of immune evasion [6] , we evaluated whether GILT staining in melanocytes of melanoma lesions correlated with MHC class II staining. We found that GILT staining was correlated with MHC class II staining in primary melanomas, including overall staining (positive versus negative; P < 0.05), frequency (Spearman ρ = 0.505, P < 0.01), and intensity (Spearman ρ = 0.489, P < 0.01). However, in metastatic melanomas, there was no correlation between the overall staining and the intensity of staining of GILT and MHC class II, but there was a correlation between the frequencies of GILT and MHC class II staining (Spearman ρ = 0.465, P < 0.05). Less correlation between GILT and MHC class II staining in metastatic compared with primary melanomas is consistent with the independence of GILT and MHC class II expression identified in cell lines [6] . In contrast to metastatic melanoma cell lines, which expressed MHC class II and lacked GILT [6] , our study of patient specimens revealed that it was more common for metastatic melanomas with divergent expression to express GILT and lack MHC class II, as 7/19 specimens lacked both, 6/19 expressed only GILT, 5/19 expressed both, and 1/19 expressed only MHC class II.
GILT, but not MHC class II, expression in APCs is increased in primary and metastatic melanomas compared with nevi As APCs are a major cell type that presents epitopes for T-cell stimulation and as GILT expression in APCs is critical for efficient presentation of melanoma antigens [6, 8] , we evaluated GILT expression in tumor-infiltrating APCs across the lesion types. All 27 primary and 19 metastatic melanomas contained GILT-expressing APCs compared with 9/29 nevi (31%; Fig. 3a ). GILTexpressing APCs generally comprised less than 5% of the total cell mass and demonstrated intense staining, regardless of lesion type (Fig. 3b-d) . In nevi, most APCs (6/9 lesions) were peripherally distributed around the nevus melanocytes (Fig. 3d, left) . In contrast, in melanomas, the most common location of the APCs, observed in 20/27 primary and 17/19 metastatic melanomas, was a diffuse distribution throughout the tumor (Fig. 3d , middle and right). The proportion of cases with GILTexpressing APCs, the frequency of GILT-expressing APCs, and the intensity of GILT staining in APCs were increased in primary and metastatic melanomas compared with nevi. There were no differences in GILT expression in APCs between primary and metastatic melanomas. These data show that GILT expression in tumor-infiltrating APCs is more commonly found in primary and metastatic lesions compared with nevi.
Thereafter, we evaluated MHC class II expression in tumor-infiltrating APCs. In three primary melanoma cases, the MHC class II staining of APCs could not be evaluated because of intense staining of the melanoma cells. MHC class II staining was evident in APCs in 26/29 (90%) nevi, 24/24 (100%) primary melanomas, and 16/19 (84%) metastases (Fig. 3e ). In the majority of lesions, MHC class II-expressing APCs comprised less than 5% of the total cell mass and demonstrated intense staining ( Fig. 3f-h ). There were no differences in the percentage of cases with MHC class II expression in APCs nor in the frequency or intensity of MHC class II-expressing APCs among the three lesion types. These findings show similarly high expression of MHC class II in APCs of all melanocytic lesions, in contrast to GILT expression in APCs, which is higher in melanoma cases compared with nevi. These data suggest that there is no change in the APC content between benign and malignant melanocytic lesions, on the basis of equivalent MHC class II staining.
Next, we examined whether GILT expression in APCs correlated with MHC class II expression in nevi and Fisher's exact test was used to compare the overall GILT staining across the lesion types (nevus, primary melanoma, and metastatic melanoma). The Kruskal-Wallis test was used to compare the frequency and intensity of GILT staining among the three lesion types. The analyses were carried out for all patients, patients younger than 60 years, and patients who were 60 years or older. GILT, gamma-interferon-inducible lysosomal thiol reductase.
melanomas. GILT staining did not correlate with MHC class II staining in nevi in terms of overall staining (positive versus negative), frequency, or intensity. In contrast, there was some correlation between GILT and MHC class II staining in melanomas. The frequency of GILT staining was correlated with that of MHC class II staining in primary (Spearman ρ = 0.845, P < 0.0001) and metastatic melanomas (Spearman ρ = 0.526, P < 0.05).
There was no correlation between the intensity of GILT and MHC class II staining in metastatic melanomas. The other correlations could not be determined, because there was no variation in one of the variables. Together, these data support the fact that GILT is not constitutively expressed in tumor-infiltrating APCs of nevi and that GILT expression in tumor-infiltrating APCs is upregulated in melanoma.
GILT, but not MHC class II, expression in keratinocytes is increased in primary melanomas compared with nevi and metastatic melanomas
As keratinocytes are capable of MHC class II-restricted antigen presentation and have the potential to initiate T-cell responses [20] [21] [22] , we evaluated GILT expression in keratinocytes of melanocytic lesions. Keratinocytes could not be evaluated in one metastatic melanoma case that lacked an epidermis. GILT-expressing keratinocytes were detected in 4/29 (14%) nevi, 18/27 (67%) primary melanomas, and 1/18 (6%) metastases (Fig. 4a ). GILT staining in keratinocytes was generally confined to a cluster of keratinocytes that comprised less than 5% of the total keratinocytes and was intermediate in staining intensity (Fig. 4b-d ). The percentage of cases with GILT-expressing keratinocytes, the frequency of GILT expression in keratinocytes, and the GILT staining intensity in keratinocytes were increased in primary melanomas compared with nevi and metastases.
In comparison, MHC class II expression in keratinocytes was detected in 7/29 (24%) nevi, 8/27 (30%) primary melanomas, and 1/18 (6%) of metastatic melanomas (Fig. 4e ). In cases with MHC class II expression in keratinocytes, MHC class II-expressing keratinocytes most often comprised less than 5% of the total keratinocytes and exhibited intermediate staining intensity (Fig. 4f-h ). There were no differences in MHC class II overall staining, frequency, and intensity between keratinocytes of nevi, primary melanomas, and metastases. Together, these data show that the majority of primary melanomas contain GILT-expressing keratinocytes and that GILT, but not MHC class II, expression, frequency, and intensity in keratinocytes are increased in primary melanomas compared with nevi and metastases.
On evaluating the correlation between GILT and MHC class II expression in keratinocytes in each lesion type, we found that GILT staining was correlated with MHC class II staining in primary melanomas, including overall staining (P < 0.05), frequency (Spearman ρ = 0.492, P < 0.01), and intensity (Spearman ρ = 0.456, P < 0.05). In contrast, there was no correlation between GILT and MHC class II expression in nevi or metastatic melanomas. Together, these data show that, although GILT expression is correlated with MHC class II expression in keratinocytes of primary melanomas, GILT is more frequently detected than MHC class II.
Discussion
Here, we demonstrate that GILT expression is increased in the three cell types capable of antigen presentation in human melanoma tumors. Specifically, GILT expression is increased in (i) malignant melanocytes of primary and metastatic lesions compared with nevus melanocytes, (ii) tumor-infiltrating APCs in primary and metastatic melanomas compared with nevi, and (iii) keratinocytes in primary melanoma lesions compared with nevi and metastatic melanomas. To our knowledge, this is the first report of GILT expression in melanoma tumors ex vivo.
We found that expression of both GILT and MHC class II was increased in melanocytes of primary and metastatic lesions, whereas expression of neither GILT nor MHC class II was detected in nevus melanocytes. MHC class II expression on melanoma cells in vitro and in vivo can be induced by T-cell-derived IFN-γ or by constitutive expression of the class II transactivator (CIITA) [35] [36] [37] . Similar to MHC class II, GILT expression in melanoma cell lines is upregulated in response to IFN-γ and STAT1, the major transcription factor in response to IFN-γ signaling [6, 38] . In contrast to MHC class II expression, GILT expression in melanoma cells is independent of CIITA [38] . A previous report of human metastatic melanoma cell lines found little or no GILT expression in a panel of 16 cell lines and that the absence of GILT resulted in impaired MHC class II-restricted presentation of a natural tyrosinase epitope [6] , suggesting that the lack of GILT in MHC class II-expressing melanomas may be a mechanism of immune evasion. In contrast to data in cell lines, we detected GILT in the majority of primary and metastatic melanoma specimens. Furthermore, in metastatic melanomas, GILT expression did not correlate with MHC class II expression, but it was more common for cases to express GILT and lack MHC class II. Our data support the interpretation that both GILT and MHC class II expression are increased in melanoma cells of malignant lesions. We hypothesize that cytokines in the tumor microenvironment, such as IFN-γ, are responsible for the upregulation of GILT and MHC class II on malignant melanocytes. Further studies are needed to assess the association of T-cell infiltrates and cytokine production in the tumor with expression of antigen processing machinery by melanocytes.
Prior studies have generally identified an increased percentage of primary melanoma cases with MHC class II staining among melanocytes with increasing tumor thickness [23, 26, 28, 30, 32] . Thus, a limitation of our study is that the selection of deep primary melanomas may have biased the results, for example, by increasing the difference between primary melanomas and nevi and diminishing the difference between primary and metastatic melanomas. Nonetheless, our study supports previous studies that observed increased MHC class II expression in malignant melanocytes compared with nevus melanocytes [26, 28, 33] and no difference between the percentage of primary and metastatic cases with MHC class II staining [27, 30, 33] .
Our findings show increased GILT expression in tumorinfiltrating APCs of primary and metastatic melanomas compared with nevi, whereas uniformly high MHC class II expression in tumor-infiltrating APCs of all melanocytic lesions is observed. These data argue that the APC content is similar in benign and malignant melanocytic tumors and that GILT expression is induced in APCs in the tumor microenvironment. This finding shifts the current paradigm that GILT is constitutively expressed in professional APCs, on the basis of studies of primary APCs, including murine splenic B cells, bone marrowderived dendritic cells and macrophages, as well as human peripheral blood monocytes and tonsillar B cells and dendritic cells [3] [4] [5] . In contrast to evidence pointing to constitutive expression of GILT in professional APCs [3] [4] [5] , the data presented here support the fact that GILT expression in tumor-infiltrating APCs can be regulated and suggest that APCs respond to the tumor microenvironment with changes in antigen processing machinery that improve MHC class II-restricted presentation. GILT expression can be induced or increased in APCs by IFN-γ as well as the inflammatory cytokines TNF and IL-1β [6, 7, 39, 40] . Elevated IFN-γ levels have been identified in melanoma lesions, and melanoma cells can produce TNF and IL-1β [41] [42] [43] [44] [45] [46] . These findings suggest that T-cell-derived IFN-γ or inflammatory cytokines produced by melanoma cells or activated APCs may be responsible for increased GILT expression in tumor-infiltrating APCs. Future studies will address the mechanism of upregulated expression and the characteristics of the tumor-infiltrating APCs in which GILT expression is induced.
We show that GILT expression in keratinocytes is increased in primary melanomas compared with nevi and metastatic melanomas. To our knowledge, this is the first report of GILT expression in keratinocytes. We propose that GILT expression is increased in primary melanoma lesions compared with metastatic lesions because of the proximity of keratinocytes to the tumor microenvironment in primary lesions and exposure to cytokines known to induce GILT in other cell types [6, 7, 39, 40] . In addition, keratinocytes are capable of producing TNF and IL-1β [47] [48] [49] [50] [51] [52] , which may contribute to the induction of GILT expression. Our results are consistent with one of three melanoma cases demonstrating MHC class II expression in keratinocytes [16] . MHC class II expression on keratinocytes can be induced by IFN-γ, and epidermal growth factor receptor inhibitors have been shown to augment IFN-γ induced MHC class II expression on keratinocytes [53, 54] .
GILT expression in melanoma tumors is predicted to enhance antigen presentation and improve melanomaspecific T-cell responses. Diminished antigen presentation in tissues can induce suppressive, regulatory T cells [55, 56] , and, therefore, the absence of GILT in tumors is predicted to be associated with increased regulatory T cells. In fact, in a mouse model, increased melanoma-specific regulatory T cells are observed in the absence of GILT expression [57] . Melanoma-specific T-cell responses are critical, because T-cell-mediated immunity is capable of recognizing and destroying melanoma. The presence of brisk tumorinfiltrating lymphocytes in primary melanoma is correlated with improved patient outcome, including sentinel lymph node status, recurrence, metastasis, and survival [58, 59] . Furthermore, melanoma is responsive to T-cell-directed immune-stimulating therapies such as therapeutic inhibition of immune checkpoints cytotoxic T lymphocyte-associated protein 4 and programmed cell death protein 1 [60] [61] [62] [63] . Future studies are needed to evaluate the relationship between GILT expression in the cell types capable of antigen presentation in the tumor with the tumor-infiltrating T-cell phenotype and patient outcome. We hypothesize that GILT expression in melanoma cells will be associated with improved patient outcome, similar to GILT expression in tumor cells of diffuse large B-cell lymphoma and breast cancer [5, 64] .
The potential impact of GILT expression is not limited to melanoma nor MHC class II-restricted presentation. GILT improves the MHC class II-restricted presentation of a subset of epitopes from disulfide bond-containing antigens regardless of origin, presumably through reduction of disulfide bonds relaxing the tertiary structure of antigens and exposing buried regions for MHC class II binding [1, 7] . GILT expression also improves cross-presentation of disulfide bond-containing antigens on MHC class I [65] , which is important for the activation of tumor-specific CD8 + T cells. Therefore, GILT expression in cell types capable of antigen presentation in tumors is anticipated to improve MHC class I-restricted and MHC class IIrestricted presentation of disulfide bond-containing antigens for enhanced CD4 + and CD8 + T-cell responses directed against multiple tumors.
In summary, GILT expression is upregulated in three cell types capable of antigen presentation in melanoma: melanoma cells, tumor-infiltrating APCs, and keratinocytes. GILT expression in tumors is anticipated to direct melanoma-specific T-cell responses and, ultimately, patient outcome. Induction of GILT, but not MHC II, expression in tumor-infiltrating APCs and a higher percentage of melanoma cases with GILT expression in melanocytes and keratinocytes compared with MHC class II suggest that GILT expression may be an earlier or more sensitive marker of upregulation of genes induced by IFN-γ and involved in antigen presentation. These results raise the intriguing possibility that GILT expression may be a biomarker predictive of melanomaspecific immune responses and perhaps enhanced response to T-cell-directed therapies.
